BRPI0520579A2 - composto, processo para a preparação de um composto, método para o tratamento de uma desordem do sistema nervoso central relacionada a ou afetada pelo receptor 5-ht6, composição farmacêutica, uso do composto e método para testar antagonistas e antagonistas com seletividade para o receptor 5-ht6 - Google Patents
composto, processo para a preparação de um composto, método para o tratamento de uma desordem do sistema nervoso central relacionada a ou afetada pelo receptor 5-ht6, composição farmacêutica, uso do composto e método para testar antagonistas e antagonistas com seletividade para o receptor 5-ht6Info
- Publication number
- BRPI0520579A2 BRPI0520579A2 BRPI0520579-4A BRPI0520579A BRPI0520579A2 BR PI0520579 A2 BRPI0520579 A2 BR PI0520579A2 BR PI0520579 A BRPI0520579 A BR PI0520579A BR PI0520579 A2 BRPI0520579 A2 BR PI0520579A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- receptor
- antagonists
- affected
- preparation
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 108091005435 5-HT6 receptors Proteins 0.000 title abstract 3
- 208000015114 central nervous system disease Diseases 0.000 title abstract 2
- 108020003175 receptors Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 3
- 239000005557 antagonist Substances 0.000 title 2
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 aminoaryl sulphonamide derivatives Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Semiconductor Integrated Circuits (AREA)
- Insulated Gate Type Field-Effect Transistor (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
Abstract
COMPOSTO, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO, MéTODO PARA O TRATAMENTO DE UMA DESORDEM DO SISTEMA NERVOSO CENTRAL RELACIONADA A OU AFETADA PELO RECEPTOR 5-HT~ 6~, COMPOSIçãO FARMACêUTICA, USO DO COMPOSTO E MéTODO PARA TESTAR ANTAGONISTAS E ANTAGONISTAS COM ELETIVIDADE PARA O RECEPTOR 5-HT~ 6~. A presente invenção proporciona derivados de aminoaril sulfonamida dE fórmula (I), úteis no tratamento de uma desordem do SNC relacionada a ou afetada pelo receptor 5-HT~ 6~, o perfil farmacológico los referidos compostos incluem alta afinidade de ligação com o receptor 5-HT~ 6~ aliada a uma boa seletividade em relação ao referido receptor. A presente invenção inclui também os estereoisómeros, os sais, os métodos de preparação e um medicanento contendo os referidos derivados de aminoaril sulfonamida.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1127CH2005 | 2005-08-12 | ||
| IN1127/CHE/2005 | 2005-08-12 | ||
| PCT/IN2005/000345 WO2007020652A1 (en) | 2005-08-12 | 2005-10-26 | Aminoaryl sulphonamide derivatives as functional 5-ht6 ligands. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0520579A2 true BRPI0520579A2 (pt) | 2009-11-10 |
| BRPI0520579B1 BRPI0520579B1 (pt) | 2019-08-06 |
| BRPI0520579B8 BRPI0520579B8 (pt) | 2021-05-25 |
Family
ID=36130030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0520579A BRPI0520579B8 (pt) | 2005-08-12 | 2005-10-26 | composto, processo para a preparação de um composto e composição farmacêutica |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7998981B2 (pt) |
| EP (1) | EP1919896B1 (pt) |
| JP (1) | JP5091138B2 (pt) |
| KR (1) | KR101016972B1 (pt) |
| CN (1) | CN101258144B (pt) |
| AT (1) | ATE452885T1 (pt) |
| AU (1) | AU2005335620B2 (pt) |
| BR (1) | BRPI0520579B8 (pt) |
| CA (1) | CA2618636C (pt) |
| CY (1) | CY1110276T1 (pt) |
| DE (1) | DE602005018554D1 (pt) |
| DK (1) | DK1919896T3 (pt) |
| EA (1) | EA013875B1 (pt) |
| ES (1) | ES2337167T3 (pt) |
| MX (1) | MX2008002018A (pt) |
| NO (1) | NO340511B1 (pt) |
| NZ (1) | NZ566495A (pt) |
| PL (1) | PL1919896T3 (pt) |
| PT (1) | PT1919896E (pt) |
| SI (1) | SI1919896T1 (pt) |
| WO (1) | WO2007020652A1 (pt) |
| ZA (1) | ZA200801276B (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2114878T3 (da) | 2007-01-08 | 2011-03-14 | Suven Life Sciences Ltd | 5-(Heterocyclyl)alkyl-N-(arylsulfonyl)indolforbindelser og deres anvendelse som 5-HT6-ligander |
| WO2008136017A1 (en) | 2007-05-03 | 2008-11-13 | Suven Life Sciences Limited | Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands |
| ES2370680T3 (es) * | 2007-10-26 | 2011-12-21 | Suven Life Sciences Limited | Compuestos de aminoarilsulfonamida y su empleo como ligandos de 5-ht6. |
| US8318725B2 (en) | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
| SG181992A1 (en) * | 2010-01-05 | 2012-08-30 | Suven Life Sciences Ltd | Sulfone compounds as 5-ht6 receptor ligands |
| CN102153884B (zh) * | 2011-02-16 | 2013-06-19 | 连云港清泰化工有限公司 | 一种墨水型染料及其制备方法与用途 |
| WO2015090233A1 (en) | 2013-12-20 | 2015-06-25 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
| AU2015286049B2 (en) | 2014-07-08 | 2018-03-01 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993011106A1 (en) * | 1991-11-25 | 1993-06-10 | Pfizer, Inc. | Indole derivatives |
| DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| ATE296811T1 (de) * | 1997-07-11 | 2005-06-15 | Smithkline Beecham Plc | Sulfonamid-derivate als 5-ht6 receptor antagonisten und verfahren zu ihrer herstellung |
| GB9801392D0 (en) | 1998-01-22 | 1998-03-18 | Smithkline Beecham Plc | Novel compounds |
| GB9803411D0 (en) | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
| GB9926302D0 (en) | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
| PL363238A1 (en) * | 2000-12-22 | 2004-11-15 | Wyeth | Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands |
| US7342021B2 (en) | 2001-02-08 | 2008-03-11 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
| CA2452743A1 (en) * | 2001-08-03 | 2003-02-13 | Pharmacia & Upjohn Company | 5-arylsulfonyl indoles having 5-ht6 receptor affinity |
| WO2003065046A2 (en) | 2002-02-01 | 2003-08-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor |
| EP1471912A1 (en) | 2002-02-05 | 2004-11-03 | Glaxo Group Limited | Method of promoting neuronal growth |
| US6855709B2 (en) * | 2002-02-22 | 2005-02-15 | Pharmacia & Upjohn Company | Pyridyl sulfone derivatives |
| EP1513809A1 (en) | 2002-06-05 | 2005-03-16 | F. Hoffmann-La Roche Ag | 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders |
| BR0315317A (pt) | 2002-10-18 | 2005-09-06 | Hoffmann La Roche | 4-piperazinil benzenossulfonil indóis com afinidade para o receptor de 5-ht6 |
| PT1567492E (pt) | 2002-11-28 | 2013-07-22 | Suven Life Sciences Ltd | N-arilsulfonil-3-aminoalcoxi-indóis |
| DK1581492T3 (da) | 2002-11-28 | 2008-11-10 | Suven Life Sciences Ltd | N-arylsulfonyl-3-substituerede indoler med serotoninreceptoraffinitet, fremgangsmåde til fremstilling heraf og en farmaceutisk sammensætning indeholdende disse |
| AU2003292508A1 (en) | 2002-11-28 | 2004-06-18 | Suven Life Sciences Limited | N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands |
| NZ540841A (en) | 2002-12-18 | 2008-08-29 | Suven Life Sciences Ltd | Tetracyclic 3-substituted indoles having serotonin receptor affinity |
| ES2385219T3 (es) * | 2003-09-12 | 2012-07-19 | Merck Serono Sa | Derivados de sulfonamida para el tratamiento de diabetes |
-
2005
- 2005-10-26 CA CA2618636A patent/CA2618636C/en not_active Expired - Fee Related
- 2005-10-26 ES ES05813800T patent/ES2337167T3/es not_active Expired - Lifetime
- 2005-10-26 AT AT05813800T patent/ATE452885T1/de active
- 2005-10-26 SI SI200530928T patent/SI1919896T1/sl unknown
- 2005-10-26 PT PT05813800T patent/PT1919896E/pt unknown
- 2005-10-26 JP JP2008525723A patent/JP5091138B2/ja not_active Expired - Fee Related
- 2005-10-26 DK DK05813800.9T patent/DK1919896T3/da active
- 2005-10-26 MX MX2008002018A patent/MX2008002018A/es active IP Right Grant
- 2005-10-26 US US11/990,383 patent/US7998981B2/en not_active Expired - Fee Related
- 2005-10-26 AU AU2005335620A patent/AU2005335620B2/en not_active Ceased
- 2005-10-26 EA EA200800573A patent/EA013875B1/ru not_active IP Right Cessation
- 2005-10-26 PL PL05813800T patent/PL1919896T3/pl unknown
- 2005-10-26 DE DE602005018554T patent/DE602005018554D1/de not_active Expired - Lifetime
- 2005-10-26 EP EP05813800A patent/EP1919896B1/en not_active Expired - Lifetime
- 2005-10-26 KR KR1020087005968A patent/KR101016972B1/ko not_active Expired - Fee Related
- 2005-10-26 NZ NZ566495A patent/NZ566495A/en not_active IP Right Cessation
- 2005-10-26 BR BRPI0520579A patent/BRPI0520579B8/pt not_active IP Right Cessation
- 2005-10-26 WO PCT/IN2005/000345 patent/WO2007020652A1/en not_active Ceased
- 2005-10-26 CN CN2005800515505A patent/CN101258144B/zh not_active Expired - Fee Related
-
2008
- 2008-02-06 ZA ZA200801276A patent/ZA200801276B/xx unknown
- 2008-02-08 NO NO20080705A patent/NO340511B1/no not_active IP Right Cessation
-
2010
- 2010-02-04 CY CY20101100110T patent/CY1110276T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT1919896E (pt) | 2010-02-26 |
| HK1116796A1 (en) | 2009-01-02 |
| US20100168168A1 (en) | 2010-07-01 |
| CA2618636A1 (en) | 2007-02-22 |
| CA2618636C (en) | 2011-01-18 |
| ES2337167T3 (es) | 2010-04-21 |
| ZA200801276B (en) | 2009-02-25 |
| SI1919896T1 (sl) | 2010-04-30 |
| AU2005335620B2 (en) | 2009-12-10 |
| DE602005018554D1 (de) | 2010-02-04 |
| EP1919896B1 (en) | 2009-12-23 |
| CY1110276T1 (el) | 2015-01-14 |
| NO20080705L (no) | 2008-05-06 |
| WO2007020652A1 (en) | 2007-02-22 |
| PL1919896T3 (pl) | 2010-05-31 |
| MX2008002018A (es) | 2008-03-27 |
| AU2005335620A1 (en) | 2007-02-22 |
| DK1919896T3 (da) | 2010-04-19 |
| CN101258144B (zh) | 2012-05-30 |
| BRPI0520579B8 (pt) | 2021-05-25 |
| KR101016972B1 (ko) | 2011-02-25 |
| EA200800573A1 (ru) | 2008-08-29 |
| KR20080039984A (ko) | 2008-05-07 |
| JP2009504633A (ja) | 2009-02-05 |
| ATE452885T1 (de) | 2010-01-15 |
| US7998981B2 (en) | 2011-08-16 |
| BRPI0520579B1 (pt) | 2019-08-06 |
| NZ566495A (en) | 2010-06-25 |
| CN101258144A (zh) | 2008-09-03 |
| JP5091138B2 (ja) | 2012-12-05 |
| EA013875B1 (ru) | 2010-08-30 |
| EP1919896A1 (en) | 2008-05-14 |
| NO340511B1 (no) | 2017-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0312020A (pt) | Método de tratamento de distúrbios, compostos, composições farmacêuticas, e, uso de um composto | |
| BR0208253A (pt) | Compostos, composições farmacêuticas, método de preparação de composições farmacêuticas, processo para preparação de compostos, e, uso de um composto | |
| BR0212044A (pt) | Compostos, composições farmacêuticas, método de preparação das mesmas, e, uso de um composto | |
| BRPI0911681B8 (pt) | composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula in vitro | |
| BRPI0517423A (pt) | composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto | |
| BRPI0910182A2 (pt) | composto de fórmula (i), composição farmacêutica, método de tratamento de um distúrbio e uso de um composto" | |
| BR0212481A (pt) | Composto, composição farmacêutica, método de preparação de uma composição farmacêutica, processo para a preparação de um composto, e, uso de um composto | |
| BRPI0414514A (pt) | uso de um composto, composto, e, composições farmacêuticas | |
| BRPI0518459A2 (pt) | composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo | |
| DOP2009000133A (es) | Derivados de indol como agonistas de los receptores s1p1 | |
| BRPI0510170B8 (pt) | composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto | |
| BRPI0514537B8 (pt) | compostos de aminoeteroarila substituídos com pirazol e composição farmacêutica que os compreende | |
| BRPI1006602A2 (pt) | composto, método para modular um receptor de histamina em um indivíduo, composição farmacêutica, kit e método para tratar um distúrbio cognitivo ou um distúrbio induzido por pelo menos um sintoma associado com a alteração da cognição | |
| BRPI0607796A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica | |
| ATE482210T1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
| BR0208179A (pt) | Composto, composição farmacêutica, métodos para tratar distúrbios associados com o receptor 5-ht6, distúrbios cognitivos, distúrbios da mémoria, psicose, esquizofrenia, e ansiedade, e, uso de um composto | |
| BR0211124A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para alterar a atividade de transdução de sinal de receptores gabaa, para o tratamento de ansiedade, depressão, distúrbio do sono, esquizofrenia, distúrbio de hiperatividade-falta de atenção, ou para a melhora de memória, e para demonstrar a presença de receptores gabaa em uma célula ou amostra de tecido, composição farmacêutica embalada, e, uso de um composto ou sal | |
| ECSP088326A (es) | Derivados de benzotiazol ciclobutil amina y su uso como ligandos de los receptores 3 de histamina | |
| BR0306150A (pt) | Composto, uso de um composto, e, composição farmacêutica | |
| NO20076344L (no) | Piperazin-piperidin-antagonister og agonister av 5-HT1A-reseptoren | |
| BRPI0814382A2 (pt) | Composto, uso do composto, e, composição farmacêutica | |
| CY1110276T1 (el) | Αμινοαρυλο σουλφοναμιδικα παραγωγα ως λειτουργικοι συνδετες 5-ητ6 | |
| BRPI0517438A (pt) | composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica | |
| NO20074977L (no) | Fuserte tiazolderivater med affinitet for histamin H3 receptoren | |
| BRPI0612189A2 (pt) | composto, composiÇço farmacÊutica, mÉtodo para ligar receptores opiàides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO O PARECER DA PROCURADORIA NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 3A ANUIDADE. |
|
| B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2162 DE 12/06/2012. |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/10/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 16A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2641 DE 17-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |